|
|
 |
| Stemgent® Oct4-neo MEF (P2) |
|
| Description |
| Stemgent® Oct4-neo mouse embryonic fibroblasts (MEF) harbor a neomycin resistance gene downstream of exon 5 of the endogenous Oct4 gene. Upon successful reprogramming of Stemgent® Oct4-neo MEFs, the neo gene will be expressed in the resulting induced pluripotent stem (iPS) cells. Use of neomycin (or G418) during reprogramming aids in the selection of iPS cell colonies by eliminating partially reprogrammed MEFs. The establishment of neomycin-resistant colonies can be used as an indicator of successful reprogramming. Stemgent scientists have demonstrated iPS cell generation from the Stemgent® Oct4-neo MEFs. |
| Disclaimer |
| This Stemgent® Product is exclusively distributed by Miltenyi Biotec outside the USA and Israel. |
| Specifications and technical documents |
| Specification SheetsMaterial Safety Data SheetsProtocols
|
| | |
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| Stemgent Oct4-neo MEF (P2) |
- ~ 1×106 cells per vial
- Stemgent Catalog # 08-0014
130-095-688
|
|
| References |
| 1. Wernig et al. (2007) Nature 448: 318–324. |
|
| MACS Stem Cell newsletter |
|
Stay current with important developments in stem cell research by subscribing to
Stem Cell Updates.
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
